Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity
I'm PortAI, I can summarize articles.
Biomea Fusion Inc. has launched a Phase I trial for its oral GLP-1 agonist, BMF-650, aimed at obesity treatment. Preclinical data presented at ObesityWeek® 2025 showed significant weight loss and improved glycemic control in obese monkeys. The trial is currently enrolling healthy obese patients, with results expected in early 2026. Additionally, Biomea plans to evaluate its menin inhibitor, icovamenib, in type 2 diabetes patients by late 2025, with first dosing anticipated in early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments